Literature DB >> 19578086

Lithium and chronic kidney disease.

Mukesh Kripalani1, James Shawcross, Joe Reilly, John Main.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19578086     DOI： 10.1136/bmj.b2452

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

1.  Will lithium damage my kidneys?

Authors:  Thomas J Raedler
Journal:  J Psychiatry Neurosci       Date:  2012-05       Impact factor: 6.186

2.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

3.  Lithium nephrotoxicity.

Authors:  Abed N Azab; Alla Shnaider; Yamima Osher; Dana Wang; Yuly Bersudsky; R H Belmaker
Journal:  Int J Bipolar Disord       Date:  2015-06-05

4.  Renal failure in lithium-treated bipolar disorder: a retrospective cohort study.

Authors:  Helen Close; Joe Reilly; James M Mason; Mukesh Kripalani; Douglas Wilson; John Main; A Pali S Hungin
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

5.  Drug information update. Lithium and chronic kidney disease: debates and dilemmas.

Authors:  Sumeet Gupta; Udayan Khastgir
Journal:  BJPsych Bull       Date:  2017-08

Review 6.  Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification.

Authors:  J Davis; M Desmond; M Berk
Journal:  BMC Nephrol       Date:  2018-11-03       Impact factor: 2.388

Review 7.  Lithium Treatment Over the Lifespan in Bipolar Disorders.

Authors:  Constantin Volkmann; Tom Bschor; Stephan Köhler
Journal:  Front Psychiatry       Date:  2020-05-07       Impact factor: 4.157

8.  Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young
Journal:  J Psychopharmacol       Date:  2016-03-15       Impact factor: 4.153
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.